Description

30,000 commercial papers of Titan Company Limited with face value of Rs. 5 lakhs each listed on BSE Debt segment, maturing on March 9, 2026.

Summary

Titan Company Limited has listed 30,000 new commercial papers on the BSE Debt segment on December 10, 2025. These instruments were issued on a private placement basis with a face value of Rs. 5,00,000 each, aggregating to Rs. 15,000 crores. The commercial papers carry a CARE A1+ credit rating and will mature on March 9, 2026. ICICI Bank Limited serves as the issuing and paying agent.

Key Points

  • Quantity: 30,000 commercial papers
  • Face Value: Rs. 5,00,000 per unit
  • Issue Price: Rs. 4,92,650.50 per unit
  • Market Lot: 1 unit
  • ISIN: INE280A14500
  • Scrip Code: 730728
  • Scrip ID: TCL91225
  • Credit Rating: CARE A1+
  • Allotment Date: December 9, 2025
  • Redemption Date: March 9, 2026
  • Tenure: 90 days
  • Trading format: Dematerialized only
  • Standard denomination: Rs. 5 lakhs and multiples thereof
  • Tick size: 1 paise

Regulatory Changes

No regulatory changes announced in this circular.

Compliance Requirements

  • Trading members must trade these securities only in dematerialized form under ISIN INE280A14500
  • Trading must be conducted in standard denomination of Rs. 5 lakhs and multiples thereof
  • Tick size of 1 paise must be observed for all transactions

Important Dates

  • Allotment Date: December 9, 2025
  • Listing Date: December 10, 2025
  • Redemption Date: March 9, 2026

Impact Assessment

This is a routine debt instrument listing with minimal market impact. The commercial paper provides short-term financing to Titan Company Limited for 90 days. The high credit rating (CARE A1+) indicates low credit risk. Trading will be restricted to the debt segment with no impact on equity markets. The listing expands debt market options for institutional investors seeking short-term, high-quality paper from a blue-chip company.

Impact Justification

Routine commercial paper listing by established company with short 90-day tenure, no impact on equity trading or broad market operations